Krystal Biotech, Inc. (KRYS)

Krystal Biotech, Inc. (KRYS) is a healthcare company (biotechnology) based in the United States. The share price is $297.37, down 0.18% on the day, which values the company at $8.81B. Price as of 17 Nov 2026, 17:16 UTC, from Yahoo Finance.

Key facts

Share price
$297.37−0.18% today
Market value
$8.81B
P/E ratio
40.4×last 12 months
Forward P/E
32.2×
Funk Score
73/100
Against its own history
Above its usual priceusual price $246.54
200-week average
$185.5760% above
Sector
Healthcare

Figures as of . Prices from Yahoo Finance (may be delayed); statements from company filings with the SEC and Yahoo Finance. Estimates, not advice.

Krystal Biotech, Inc. in more detail

KRYS trades at 40.4× its last twelve months' earnings, 32.2× next year's expected earnings, 18.7× sales. Measured against its own history, the price is 21% above what its usual multiples would imply ($246.54) — above its usual price. It sits 60% above its 200-week average of $185.57.

Its Funk Score is 73 out of 100 (financial strength 9.2, profitability 8.6, value 4.2, each out of 10).

In its favour: Altman Z in the safe zone; More cash than debt. Worth checking: Share count keeps rising; Heavy stock-based pay.

Compare

Health Care companies of similar size

Side by side:KRYS vs PTGX (Krystal Biotech, Inc. vs Protagonist Therapeutics)KRYS vs TWST (Krystal Biotech, Inc. vs Twist Bioscience)KRYS vs PRAX (Krystal Biotech, Inc. vs Praxis Precision Medicines)KRYS vs TXG (Krystal Biotech, Inc. vs 10x Genomics)KRYS vs HQY (Krystal Biotech, Inc. vs HealthEquity)

All health care companies by market valueLargest companies in the United StatesAll stocks A–Z

Krystal Biotech, Inc. (KRYS): questions and answers

What is KRYS's P/E ratio?

Krystal Biotech, Inc. trades at 40.4× its last twelve months' earnings and 32.2× next year's expected earnings. At its fiscal year-ends over the past 3 years the P/E ranged from 36.0× to 318.1×, with a median of 52.2×.

What is Krystal Biotech, Inc.'s market cap?

Krystal Biotech, Inc. is valued at $8.81B at a share price of $297.37.

Is KRYS overvalued or undervalued?

Against its own history, KRYS is above its usual price: the price is 21% above the $246.54 implied by the median multiples it has traded at (price / earnings, price / sales, price / book). That compares the stock with its past; it does not say whether the business now deserves a higher or lower multiple.

Is KRYS above its 200-week moving average?

Yes. KRYS is 60.2% above its 200-week average of $185.57. Long-term investors watch that line because strong companies rarely trade below it for long.

Does KRYS pay a dividend?

Krystal Biotech, Inc. does not currently pay a regular dividend.

Cite this page

Funkfolio, “Krystal Biotech, Inc. (KRYS) stock: price, valuation and fundamentals”, data as of 17 November 2026. https://funkfolio.com/stock/KRYS

Underlying data: Yahoo Finance; company filings with the SEC.